[Losartan].
Quetglas
E G
EG
Servicio de Farmacología Clínica, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra.
Sádaba
B
B
Escolar
M
M
Honorato
J
J
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008658:Inactivation, Metabolic; D007231:Infant, Newborn; D007668:Kidney / Q000098:blood supply / Q000187:drug effects; D019808:Losartan / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009318:Natriuresis / Q000187:drug effects; D011247:Pregnancy; D012449:Safety
D000959:Antihypertensive Agents; D000804:Angiotensin II; D019808:Losartan
Losartan.